{"article":{"annotation":{"article_id":"brazil-anvisa-bans-irregular-medicines-october-2026","available_at":"2026-10-06T23:11:48.041355Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"9b4ec96012aa0c05605eea6f054fda9f375efca6fcac5c933ef48d5f1453c661","input_sha256":"45da2698cdfa8ef808029fa48b777229256690afeaa975a53200bd994e60f02e","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"BR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"geometry":null,"id":"iso3166-1:BR","kind":"country-or-area","labels":{"ar":"البرازيل","en":"Brazil","es":"Brasil","fr":"Brésil"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"d28c9c89703b56bd91fd887965d416d0115c2473d4bfbd3e558bcceafc3941dd","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","category":"health","content":{"key_points":[],"paragraphs":["El regulador sanitario de Brasil, Anvisa, prohibió la venta de varios medicamentos irregulares el 6 de octubre. Las medidas abarcan insulina glargina distribuida por una empresa sin autorización, un medicamento compuesto comercializado al público sin receta y péptidos sin registro.","Anvisa también informó del retiro voluntario por el fabricante de un lote de Imaavy y ordenó retirar un lote del antibiótico Lizbi tras confirmar pérdida de esterilidad por daños en el envase. Este artículo informa sobre medidas regulatorias y no es un consejo de tratamiento individual."],"sections":[]},"corrections":[{"at":"2026-10-07T00:55:00+03:00","language":"es","text":"Se añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones."}],"country":"BR","data":{"blocks":[{"columns":[{"key":"item","label":{"ar":"المنتج أو الفئة","de":"Produkt oder Kategorie","en":"Product or category","es":"Producto o categoría","fr":"Produit ou catégorie","pt":"Produto ou categoria","tr":"Ürün veya kategori"},"language":"en","type":"text"},{"key":"action","label":{"ar":"إجراء أنفيسا","de":"Maßnahme von Anvisa","en":"Anvisa action","es":"Medida de Anvisa","fr":"Mesure de l’Anvisa","pt":"Medida da Anvisa","tr":"Anvisa işlemi"},"language":"en","type":"text"}],"description":{"ar":"فئات المنتجات وأنواع الإجراءات في إعلان أنفيسا بتاريخ 6 أكتوبر 2026.","de":"Produkte und Maßnahmen in der Mitteilung von Anvisa vom 6. Oktober 2026.","en":"Products and action types in Anvisa’s October 6, 2026 notice.","es":"Productos y tipos de medidas del aviso de Anvisa del 6 de octubre de 2026.","fr":"Produits et types de mesures dans l’avis de l’Anvisa du 6 octobre 2026.","pt":"Produtos e tipos de medida no comunicado da Anvisa de 6 de outubro de 2026.","tr":"Anvisa’nın 6 Ekim 2026 duyurusundaki ürün grupları ve karar türleri."},"id":"brazil-anvisa-regulatory-actions","methodology":{"ar":"يلخص الجدول نطاق الإعلان وفق نص المصدر؛ ولا يقدم إرشاداً طبياً.","de":"Die Tabelle fasst den Umfang der Mitteilung mit den Begriffen der Quelle zusammen und enthält keine medizinische Beratung.","en":"The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.","es":"La tabla resume el alcance del aviso según el texto fuente; no ofrece orientación médica.","fr":"Le tableau résume le champ de l’avis selon le texte source ; il ne fournit pas de conseil médical.","pt":"A tabela resume o escopo do comunicado nos termos da fonte; não fornece orientação médica.","tr":"Tablo karar kapsamını kaynak metindeki ifadelerle özetler; listelenen ilaçlar için tıbbi öneri içermez."},"rows":[{"action":"Sale of all lots prohibited; distributor lacked authorization.","item":"Insulin glargine 3 mL/100 IU, Costa Mar"},{"action":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","item":"Vermefree compounded medicine, Sintonia Pharma"},{"action":"Sale, manufacture, distribution, advertising, transport and use prohibited.","item":"Unregistered peptides listed in notice"},{"action":"Voluntary recall reported; possible glass particles in vials.","item":"Imaavy batch JNYJ1201"},{"action":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","item":"Lizbi batch 0000207107"}],"sourceUrls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"],"title":{"ar":"الأدوية المحظورة أو المسحوبة","de":"Verbotene oder zurückgerufene Arzneimittel","en":"Medicines prohibited or recalled","es":"Medicamentos prohibidos o retirados","fr":"Médicaments interdits ou rappelés","pt":"Medicamentos proibidos ou recolhidos","tr":"Yasaklanan veya geri çağrılan ilaçlar"},"type":"table","updatedAt":"2026-10-07T00:55:00+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=es&format=csv","json":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=es&format=json"},"id":"brazil-anvisa-regulatory-actions"}],"data_types":["table"],"editorial_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-8ff1924c-3faa-55d0-982f-f85ffe24522b","event_period":"2026-10-06","event_period_basis":"event-or-reference-period","id":"brazil-anvisa-bans-irregular-medicines-october-2026","image":null,"importance":0.6,"language":"es","modified_at":"2026-10-07T00:55:00+03:00","publication_basis":"publication-record","published_at":"2026-10-06T17:11:49+00:00","reading_minutes":1,"region":"world","section_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"brazil-anvisa-bans-irregular-medicines-october-2026","sources":[{"checkedAt":"2026-10-06","name":"National Health Surveillance Agency of Brazil","publishedAt":"2026-10-06","url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"}],"summary":"Las prohibiciones abarcan insulina distribuida sin autorización, un producto compuesto de forma irregular y péptidos sin registro, además de dos lotes con problemas de calidad.","text":"Las prohibiciones abarcan insulina distribuida sin autorización, un producto compuesto de forma irregular y péptidos sin registro, además de dos lotes con problemas de calidad.\n\nEl regulador sanitario de Brasil, Anvisa, prohibió la venta de varios medicamentos irregulares el 6 de octubre. Las medidas abarcan insulina glargina distribuida por una empresa sin autorización, un medicamento compuesto comercializado al público sin receta y péptidos sin registro.\n\nAnvisa también informó del retiro voluntario por el fabricante de un lote de Imaavy y ordenó retirar un lote del antibiótico Lizbi tras confirmar pérdida de esterilidad por daños en el envase. Este artículo informa sobre medidas regulatorias y no es un consejo de tratamiento individual.\n\nSe añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones.","title":"Anvisa prohíbe la venta de medicamentos irregulares en Brasil","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026"}],"url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},"version":"1"}